medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2019, Number 1

<< Back Next >>

Ann Hepatol 2019; 18 (1)

Treatment with Melatonin Improves Cognitive Behavior and Motor Skills in a Rat Model of Liver Fibrosis

Haeger P, Bouchet A, Ossandon C, Bresky G

Language: English
References: 37
Page: 101-108
PDF size: 233.89 Kb.


ABSTRACT

Introduction and aim. Patients with liver cirrhosis (LC) and minimal hepatic encephalopaty have a higher accident rate. LC impairs the normal sleep-awake cycle and produces disturbances in behavior, cognition and motor skills. Abnormal melatonin (MT) levels have also been identified in LC. Administration of MT may regulate circadian rhythms and prevent the oxidative damage. We studied the effects of MT on spatial memory acquisition (SMA) and motor skills in a liver fibrosis model (LF)s. Materials and methods. Forty-five rats, divided into 4 groups. [G1: LF; G2: LF + MT; G3: MT; G4: Healthy control (HC)]. LF was induced by carbon tetrachloride intraperitoneal injection (0.2 mL/kg) for 5 months. MT was administered during 5 weeks (0.4 mg/kg/day). SMA was evaluated by using the Morris Water Maze protocol where the escape latency (EL) and mean speed were measured. Data were registered by SMART®. Results. The EL measurement analyzed by two way ANOVA: cirrhosis presented a higher EL than controls or those treated with MT suggesting impaired memory acquisition which is rescued by MT treatment. The mean speed analysis revealed that LF presented higher speed than LF+MT or HC, suggesting that LF affects motor skills, which are improved by MT. To discard whether EL is affected by altered motor skills in LF treated with MT, we compared the average EL and speed between days 2 and 6 of the training protocol. Speed was not improved during the trials unlike EL, suggesting that memory acquisition is independent of motor skills. Conclusion. These findings suggest that MT improves cognition and motor skills in the LF model.


REFERENCES

  1. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray C, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 12: 145.

  2. Available from: http://deis.minsal.cl/deis/indicadores/ Folleto_IBS_2011.pdf

  3. Available from: http://epi.minsal.cl/epi/html/invest/cargaenf2008/ minuta21-07-2008.pdf

  4. Parkash O, Iqbal R, Jafri F, Azam I, Jafri W. Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. BMC Res Notes 2012; 20(5):446.

  5. Orr JG, Homer T, Ternent L, Newton J, McNeil CJ, Hudson M, Jones DE. Health related quality of life in people with advanced chronic liver disease. J Hepatol 2014; 61: 1158-65.

  6. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48: 1622-6.

  7. Samanta J, Dhiman RK, Khatri A, Thumburu KK, Grover S, Duseja A, Chawla Y. Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis. Metab Brain Dis 2013; 28: 249-59.

  8. Montagnese S, De Pittà C, De Rui M, Corrias M, Turco M, Merkel C, Amodio P, et al. Sleep-wake abnormalities in patients with cirrhosis. Hepatology 2014; 59: 705-12.

  9. Savlan I, Liakina V, Valantinas J. Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy. Medicina 2014; 50: 75-81.

  10. Bajaj J-S. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14: 3609.

  11. Bao Z-J, Qiu DK, Ma X, Fan ZP, Zhang GS, Huang YQ, Yu XF, et al. Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy. World J Gastroenterol 2007; 13: 3003-8.

  12. Wang JY, Zhang NP, Chi B-R, Mi YQ, Meng LN, Liu YD, Wang JB, et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol 2013; 19: 4984-91.

  13. Román E, Córdoba J, Torrens M, Torras X, Villanueva C, Vargas V, Guarner C, et al. Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol 2011; 106: 476-82.

  14. Felipo V, Urios A, Valero P, Sánchez M, Serra MA, Pareja I, Rodriguez F, et al. Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy. Liver Int 2013; 33: 1478-89.

  15. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739-45.

  16. Bajaj JS, Thacker LR, Leszczyszyn D, Taylor SA, Heuman DM, Raman S, Sterling RK, et al. Effects of Obstructive Sleep Apnea on Sleep Quality, Cognition, and Driving Performance in Patients with Cirrhosis. Clin Gastroenterol Hepatol 2015; 13: 390-7.

  17. Velissaris D, Karamouzos V, Polychronopoulos P, Karanikolas M. Chronotypology and melatonin alterations in minimal hepatic encephalopathy. J Circadian Rhythms 2009; 7: 6.

  18. Chojnacki C, Wachowska-Kelly P, Blasiak J, Reiter R, Chojnacki J.Melatonin secretion and metabolism in patients with hepatic encephalopathy. J Gastroenterol Hepatol 2013; 28: 342-7.

  19. De Rui M, Middleton B, Sticca A, Gatta A, Amodio P, Skene DJ, Montagnese S. Sleep and Circadian Rhythms in Hospitalized Patients with Decompensated Cirrhosis: Effect of Light Therapy. Neurochem Res 2015; 40: 284-92.

  20. Tan D-X, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42.

  21. Konturek SJ, Konturek PC, Brzozowska I, Pawlik M, Sliwowski Z, Czesnikiewicz-Guzik M, et al. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol 2007; 58: 381-405.

  22. Brzozowski T, Konturek PC, Zwirska-Korczala K, Konturek SJ, Brzozowska I, Drozdowicz D, Zbigniew Sliwowski, et al. Importance of the pineal gland, endogenous prostaglandins and sensory nerves in the gastroprotective actions of central and peripheral melatonin against stress-induced damage. J Pineal Res 2005; 39: 375-85.

  23. Marques TG, Chaib E, da Fonseca JH, Lourenço AC, Silva FD, Ribeiro MA Jr, Galvão FH, et al. Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. Acta Cir Bras 2012; 27: 589-94.

  24. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, Rasmussen DD. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141: 487-97.

  25. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1: 848-58.

  26. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.

  27. Shawcross DL, Wright G, Olde Damink SWM, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007; 22: 125-38.

  28. Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat Rev Neurosci 2013; 14: 851-8.

  29. Monfort P, Erceg S, Piedrafita B, Llansola M, Felipo V. Chronic liver failure in rats impairs glutamatergic synaptic transmission and long-term potentiation in hippocampus and learning ability. Eur J Neurosci 2007; 25: 2103-11.

  30. Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res 2013; 23: 267-300.

  31. Edalat-Nejad M, Haqhverdi F, Hossein-Tabar T, Ahmadian M. Melatonin improves sleep quality in hemodialysis patients. Indian J Nephrol 2013; 23: 264-9.

  32. Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Rademaker AW, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 2014; 71: 463-9.

  33. Srinivasan V, Cardinali DP, Srinivasan US, Kaur C, Brown GM, Spence DW, Hardeland R, et al. Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord 2011; 4: 297-317.

  34. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci 1994; 91: 1824-8.

  35. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.

  36. Van der Heijden KB, Smits MG, Van Someren EJW, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry 2007; 46: 233-41.

  37. Wurtman RJ, Axelrod J, Potter LT. The uptake of h3-melatonin in endocrine and nervous tissues and the effects of constant light exposure. J Pharmacol Exp Ther 1964; 143: 314-8.




2020     |     www.medigraphic.com